Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Heath

Showing results (121-130 of 248) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancerH Shiga, E I Heath, A A Rasmussen, et al.
Investigational New Drugs|June 25, 2008
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumorsPatricia Lorusso, Elisabeth I Heath, Jesse McGreivy, et al.
Cancer Chemotherapy and Pharmacology|December 9, 2010
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsElisabeth I Heath, George R Blumenschein, Roger B Cohen, et al.
Preventive Medicine Reports|July 14, 2023
The impact of high intensity interval training in a diverse group of cancer survivors: CAPABLE, a pilot studyJennifer L Beebe-Dimmer, David G Finlay, Julie J Ruterbusch, et al.
Clinical Prostate Cancer|October 4, 2005
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, Melvin Gaskins, Henry C Pitot, et al.
Journal of Immunotherapy and Precision Oncology|April 24, 2025
Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate CancerKaren A Autio, Deaglan J McHugh, Dana E Rathkopf, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2011
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancerVincent Chung, Elisabeth I Heath, William R Schelman, et al.
Advances in Radiation Oncology|July 21, 2021
A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate CancerMuhammad Hamid, Lance K Heilbrun, Jordan Maier, et al.
Investigational New Drugs|September 3, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancerElisabeth I Heath, Wei Chen, Lance Heilbrun, et al.
International Journal of Molecular Sciences|July 2, 2021
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer CellsMd Hafiz Uddin, Yiwei Li, Husain Yar Khan, et al.
Pageof 25

Showing results (121-130 of 248) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancerH Shiga, E I Heath, A A Rasmussen, et al.
Investigational New Drugs|June 25, 2008
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumorsPatricia Lorusso, Elisabeth I Heath, Jesse McGreivy, et al.
Cancer Chemotherapy and Pharmacology|December 9, 2010
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsElisabeth I Heath, George R Blumenschein, Roger B Cohen, et al.
Preventive Medicine Reports|July 14, 2023
The impact of high intensity interval training in a diverse group of cancer survivors: CAPABLE, a pilot studyJennifer L Beebe-Dimmer, David G Finlay, Julie J Ruterbusch, et al.
Clinical Prostate Cancer|October 4, 2005
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, Melvin Gaskins, Henry C Pitot, et al.
Journal of Immunotherapy and Precision Oncology|April 24, 2025
Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate CancerKaren A Autio, Deaglan J McHugh, Dana E Rathkopf, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2011
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancerVincent Chung, Elisabeth I Heath, William R Schelman, et al.
Advances in Radiation Oncology|July 21, 2021
A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate CancerMuhammad Hamid, Lance K Heilbrun, Jordan Maier, et al.
Investigational New Drugs|September 3, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancerElisabeth I Heath, Wei Chen, Lance Heilbrun, et al.
International Journal of Molecular Sciences|July 2, 2021
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer CellsMd Hafiz Uddin, Yiwei Li, Husain Yar Khan, et al.
Pageof 25